In This Story
Solventum Corporation (SOLV-1.10%) has submitted its 10-Q filing for the quarterly period ended September 30, 2024.
The filing includes financial statements for the quarter, showing total net sales of $2,082 million, a slight increase from $2,074 million in the same quarter the previous year.
Operating income for the quarter was $275 million, down from $504 million in the previous year, primarily due to increased costs associated with the company's transition to a standalone entity.
Net income for the quarter was $122 million, compared to $460 million in the previous year. Basic and diluted earnings per share were $0.70, down from $2.66 in the previous year.
Cash provided by operating activities was $966 million, while cash used in investing and financing activities was $253 million and $136 million, respectively.
Solventum had cash and cash equivalents of $772 million as of September 30, 2024, with $570 million held by foreign subsidiaries.
The filing details various financial agreements, including a five-year $2.0 billion unsecured revolving credit facility and a commercial paper program allowing up to $2.0 billion in short-term notes.
Solventum's MedSurg segment reported net sales of $1,182 million, with organic sales growth driven by I.V. site management and medical OEM products.
The Dental Solutions segment saw a decrease in net sales to $313 million, attributed to lower volumes and the impact of divestitures.
The Health Information Systems segment reported net sales of $326 million, with growth driven by the adoption of the 3MTM 360 EncompassTM.
Purification and Filtration segment sales were $238 million, with growth in bioprocessing filtration offset by declines in other categories.
The company continues to focus on managing costs associated with its separation from 3M (MMM-2.36%) and establishing its operations as a standalone entity.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Solventum Corporation quarterly 10-Q report dated November 8, 2024. To report an error, please email earnings@qz.com.